SBL
LKFT

Sargent Bickham Lagudis’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Sargent Bickham Lagudis’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30
Closed -$2K – 1042
2022
Q2 		$2K Buy
+30
New +$1.78K ﹤0.01% 919

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Sargent Bickham Lagudis's LKFT Position: Q3 2022 in Review

Sargent Bickham Lagudis sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2022, closing a stake of 30 shares — an estimated $2K sold.

Sargent Bickham Lagudis first reported a position in LKFT in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 84 funds tracked by Wall St. Rank hold LKFT as of Q3 2022.

  • Sargent Bickham Lagudis reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2022 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 30 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2022, an estimated $2K.
  • Sargent Bickham Lagudis first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2022 and held it in 1 quarter.
  • Sargent Bickham Lagudis's Lakefront Biotherapeutics American Depositary Shares position peaked at $2K in Q2 2022.
  • 84 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q3 2022, filed 27 Oct 2022.